A pharmaceutical composition and its preparation method and application
By combining the PARP inhibitor olaparib and the NF-κB inhibitor CAPE, the homologous recombination repair of GBM cells is enhanced, which solves the problems of insufficient chemotherapy drug concentration and drug resistance in existing treatment methods and achieves effective treatment of glioma.
Patent Information
- Application Number
- CN202211190263.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-28
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2042-09-28
AI Technical Summary
Existing treatments for gliomas are unable to effectively cross the blood-brain barrier, resulting in insufficient concentrations of chemotherapy drugs. Furthermore, tumor cells are prone to developing drug resistance, making it difficult for current treatments to significantly prolong patient survival.
The combined use of the PARP inhibitor olaparib and the NF-κB inhibitor CAPE enhances homologous recombination repair (HRR) in GBM cells by inhibiting the activity of NF-κB and PARP, thereby inducing synthetic lethality in glioblastoma.
It significantly enhanced the anti-tumor effect against glioblastoma, reduced colony formation, increased apoptosis rate, eliminated drug resistance, and improved treatment efficacy.
Smart Images

Figure CN115887666B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a pharmaceutical composition and a preparation method and application thereof. Background Art
[0002] At present, the treatment of glioma is divided into surgery, radiotherapy, and chemotherapy according to the effect. Because glioma grows invasively and has unclear boundaries with surrounding tissues, even if a microscope is used during surgery, it is inevitable that a small amount of tumor cells will remain, leading to tumor recurrence. Although new progress has been made in chemotherapy, it is difficult for systemic chemotherapy to pass through the blood-brain barrier, and it is difficult to achieve effective drug concentrations in the local tumor. In addition, high-dose chemotherapy causes obvious systemic toxic side effects, such as bone marrow suppression, leukopenia, and pulmonary fibrosis. Although the above three treatment methods have made significant progress, and the combined treatment of the three methods can prolong the patient's survival, glioma is still difficult to cure.
[0003] Glioblastoma multiforme (GBM) is the most aggressive primary glioma in adults. Unfortunately, despite maximal surgery, chemotherapy, and radiotherapy, the prognosis of GBM has improved little. Therefore, we urgently need to develop new diagnostic methods and more effective treatment strategies. In recent years, new therapies such as immunotherapy, anti-angiogenesis, and gene therapy have moved from the laboratory to the clinic.
[0004] Genome instability is a well-known hallmark of cancer. Thousands of DNA damage events occur in our cells every day, and we have evolved many different mechanisms to cope with them. Basically, DNA damage can be divided into two major modes, namely single-strand breaks (SSBs) and double-strand breaks (DSBs). DSBs carry the greatest risk of inducing genomic instability, and the DNA damage repair (DDR) pathway is essential for maintaining genome integrity after a wide range of damage types. There are two main mechanisms that affect DSB repair, namely non-homologous end joining (NHEJ) and homologous recombination (HR). The accumulation of DSBs requires repair. NHEJ is a more error-prone form of DSB repair, in which DNA fragments are removed and the two ends are joined without regard for homology. HR repair (HRR) is a precise process that uses sister chromatids as repair templates. The most common HR genes are BRCA1 and BRCA2, but other genes such as RAD51, ATM, BARD1, PALB2, and BRIP1 also have an impact.
[0005] There is increasing evidence that abnormal activation of DDR proteins in tumors is closely related to the resistance of tumor cells to genotoxic anti-tumor therapy. The efficient DNA repair system has become the main reason for treatment failure. A large part of the resistance is due to GBM enhancing the activity of the DNA repair system, which makes DDR therapy ineffective.
[0006] Inflammation is also considered a hallmark of cancer, contributing to the initiation and progression of cancer. A common feature of GBM is tissue necrosis with an inflammatory microenvironment. The NF-κB transcription factor is a key regulator of most, if not all, pro-inflammatory / stress-like responses. NF-κB mediates the malignant phenotype of a variety of tumors by binding to DNA as a dimer of five possible subunits (RELA / p65, c-REL, RELB, NFKB1, NFKB2). The importance of NF-κB to GBM suggests that targeting NF-κB may be an effective approach to treat GBM. Interestingly, the anti-apoptotic effect of NF-κB plays an important role in mediating GBM resistance to therapy. Inflammation or genomic instability is essential for tumor development. However, the connection between them remains unclear in GBM. We are exploring their association in GBM to seek new therapeutic approaches to treat GBM. Summary of the invention
[0007] Based on this, the purpose of the present invention is to provide a pharmaceutical composition. The applicant has found that NF-κB triggers the transcription of BRCA1, thereby enhancing the HRR of GBM. By combining the PARP inhibitor and the NF-κB inhibitor, the combined inhibition of NF-κB and PARP to induce GBM synthetic lethality can significantly enhance the anti-tumor effect.
[0008] The first object of the present invention is to provide a pharmaceutical composition comprising a PARP inhibitor and a NF-κB inhibitor, wherein the molar ratio of the NF-κB inhibitor to the PARP inhibitor is (35-40):1.
[0009] Furthermore, the PARP inhibitor is Olaparib, and the NF-κB inhibitor is CAPE (caffeic acid phenethyl ester). CAPE (caffeic acid phenethyl ester) is one of the main components of propolis, and its pharmacological effects include anti-oxidation, anti-inflammatory, and anti-tumor. The applicant has studied that the combination of CAPE and Olaparib can significantly increase the anti-tumor effect of Olaparib.
[0010] Furthermore, the molar ratio of the NF-κB inhibitor to the PARP inhibitor is 37.5:1.
[0011] Another object of the present invention is to provide a method for preparing any of the above-mentioned pharmaceutical compositions, which is obtained by mixing the PARP inhibitor and the NF-κB inhibitor in a molar ratio.
[0012] Another object of the present invention is to provide a use of any of the above-mentioned pharmaceutical compositions in the preparation of a drug for treating glioblastoma.
[0013] Furthermore, the glioblastoma includes LN229 and / or U251.
[0014] Furthermore, the PARP inhibitor and the NF-κB inhibitor in the pharmaceutical composition induce glioblastoma lethality by jointly inhibiting NF-κB and PARP.
[0015] Furthermore, the PARP inhibitor and the NF-κB inhibitor in the pharmaceutical composition induce glioblastoma lethality by jointly inhibiting the co-expression of p65 and BRCA1.
[0016] Another object of the present invention is to provide a method for treating glioblastoma, comprising administering an effective amount of any of the above-mentioned pharmaceutical compositions to a subject in need thereof.
[0017] It should be particularly noted that the focus of the present invention is to discover the anti-tumor effect of the combination of caffeic acid phenethyl ester and Olaparib, rather than the molar ratio between the above-mentioned components, because both are known compounds and have a specific effective numerical range for their dosage in mammals. Therefore, the present invention is not limited to the above-mentioned molar ratio range value, and includes all dosage ranges that can be safely used in mammals.
[0018] Compared with the prior art, the beneficial effects of the present invention are as follows:
[0019] The applicant discovered that NF-κB triggers the transcription of BRCA1, thereby enhancing the HRR of GBM. In addition, data from the CGGA and GEPIA databases show that the co-activation of NF-κB and BRCA1 leads to the worst clinical outcomes, and GBM can be more accurately molecularly stratified by NF-κB and BRCA1. Synthetic lethality of GBM is induced by the combined inhibition of NF-κB and PARP. The anti-tumor effect can be significantly enhanced by the combination of the PARP inhibitor and the NF-κB inhibitor, more preferably the combination of Olaparib and CAPE. By calculating the combined index (CI), it can be concluded that CAPE has a significant synergistic effect (CI>1) when used in combination with Olaparib, rather than just the superposition of their respective results. The applicant found that the combination of NF-κB inhibitors and PARP inhibitors induces the synthetic lethality of GBM cells, revealing an effective treatment strategy for GBM. The inventors studied the anti-tumor effect of CAPE combined with Olaparib, and found that when CAPE was used alone, the clone formation of GBM was reduced to about 35%, and apoptosis was increased by about 20%; when Olaparib was used alone, the clone formation of GBM was reduced to about 50%, and apoptosis was increased by about 40%; and when CAPE and Olaparib were used in combination, the clone formation of GBM was reduced to 5%, and apoptosis was increased to about 65%; Olaparib (PARP inhibitor) and CAPE (NF-κB inhibitor) eliminated each other's drug resistance and significantly increased the anti-tumor effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is the expression level diagram of BRCA1 or P65 in normal tissues and GBM in the GEPIA database;
[0021] Figure 2 Kaplan-Meier survival curve analysis of patients with BRCA1 or p65 at different gene expression levels in the CGGA database;
[0022] Figure 3 is the correlation between BRCA1 or p65 expression and WHO grade in the CGGA database;
[0023] Figure 4 Kaplan–Meier survival curves of BRCA1 or p65 in the three expression groups;
[0024] Figure 5 The relationships between the three expression groups and clinical case characteristics in the CGGA database;
[0025] Figure 6Immunofluorescence analysis of WT and BRCA1 KO LN229 cell lines treated or not with LPS;
[0026] Figure 7 Immunofluorescence analysis of WT and BRCA1 KO U251 cell lines treated or not with LPS;
[0027] Figure 8 Tet-DR GFP reporter analysis of WT and BRCA1 KO LN229 cell lines treated or not with LPS;
[0028] Fig. 9 Tet-DR GFP reporter analysis of WT and BRCA1 KO U251 cell lines treated or not with LPS;
[0029] Fig.10 is the inhibitory effect of DMSO or PARP inhibitor on the growth of WT and p65 KO LN229 cells;
[0030] Fig.11 The synergistic effect score of increasing doses of Olaparib combined with increasing doses of CAPE for 24 hours in LN229 or U251 cell lines;
[0031] Fig.12 Analysis of the clonogenicity of LN229 or U251 cells using CAPE, Olaparib alone, and CAPE + Olaparib combination;
[0032] Fig.13 To analyze the apoptosis of LN229 or U251 cells by CAPE, Olaparib alone, and CAPE + Olaparib combination;
[0033] Fig.14 Immunofluorescence analysis of LN229 or U251 cells using CAPE, Olaparib alone, and CAPE+Olaparib combination. DETAILED DESCRIPTION
[0034] Example 1
[0035] This example uses the data of glioblastoma in the GEPIA and CGGA databases for bioinformatics analysis, and the analysis software used is R language to verify the performance of the evaluation criteria.
[0036] The glioblastoma database was used for analysis, where:
[0037] See also Figure 1By analyzing the data in the GEPIA database, it was found that the expression levels of BRCA1 or P65 (NF-κB p65) were significantly upregulated in GBM compared with normal tissues.
[0038] See also Figure 2 By analyzing the data in the CGGA database, the patients were divided into high expression group and low expression group according to the gene expression level of BRCA1 or p65. The prognosis of the BRCA1 high expression group was worse than that of the BRCA1 low expression group, and the prognosis of the p65 high expression group was worse than that of the p65 low expression group. That is, the survival analysis curve showed that high expression of BRCA1 and high expression of p65 indicated a poor prognosis (P < 0.05).
[0039] See also Figure 3 By analyzing the data in the CGGA database, the expression of BRCA1 or p65 in GBM is significantly high in the three WHO grades (WHO Ⅱ, WHO Ⅲ, and WHO Ⅳ). The higher the WHO grade, the higher the expression level of BRCA1 or p65. That is, there is a correlation between the expression level of BRCA1 or p65 and the WHO grade, and the expression of BRCA1 or p65 is positively correlated with the poor prognosis of GBM.
[0040] See also Figure 4 According to the co-expression of p65 and BRCA1, the patients were divided into three groups: high expression group (both p65 and BRCA1 were highly expressed, i.e., p65+ / BRCA1+); medium expression group (either p65 or BRCA1 was highly expressed, i.e., p65- / BRCA1+ or p65+ / BRCA1+); low expression group (both p65 and BRCA1 were lowly expressed, i.e., p65- / BRCA1-); see Figure 4 The analysis showed that overall survival (OS) was related to the co-expression of p65 and BRCA1, among which the high expression group (p65+ / BRCA1+) had a worse OS than the intermediate expression group (p65- / BRCA1+ or p65+ / BRCA1+), and the intermediate expression group (p65- / BRCA1+ or p65+ / BRCA1+) had a worse OS than the low expression group (p65- / BRCA1-).
[0041] analyze Figure 3 and Figure 4 It can be seen that the expression of BRCA1 or p65 is significantly associated with the poor prognosis of GBM, including overall survival (OS) and WHO grade.
[0042] See also Figure 5By analyzing the relationship between the co-expression of p65 and BRCA1 and clinical pathological characteristics in the CGGA database, the analysis showed that the co-expression of p65 and BRCA1 was related to pathological tissue and WHO grade; among them, patients with glioblastoma and WHO Ⅳ had higher expression levels of p65 and BRCA1.
[0043] From the above analysis, it can be seen that the co-expression of NF-κB and BRCA1 is related to the prognosis of GBM, and OS and other clinicopathological characteristics are related to the co-expression of BRCA1 and p65.
[0044] Example 2
[0045] In this example, immunofluorescence detection and Tet-DR GFP reporter analysis were performed in WT and BRCA1 KO GBM cell lines treated with or without LPS. The effect of LPS on NF-κB activation was observed and compared after LPS treatment with that without LPS treatment.
[0046] BRCA1 was knocked out in GBM cells using CRISPR / Cas9, and then immunofluorescence and DR-GFP reporter assays were performed in WT and BRCA1 KO LN229 and U251 cell lines with or without LPS treatment.
[0047] in:
[0048] See also Figure 6 In WT and BRCA1 KO LN229 cell lines treated with or without LPS, the immunofluorescence analysis level of the BRCA1 KO group was higher than that of the WT group, indicating that the number of apoptosis in BRCA1 KO LN229 was high, indicating that BRCA1 affects the proliferation of the LN229 cell line.
[0049] See also Figure 7 In WT and BRCA1 KO U251 cell lines treated with or without LPS, the immunofluorescence analysis level of the BRCA1 KO group was higher than that of the WT group, indicating that the number of apoptosis in BRCA1 KO U251 was high, indicating that BRCA1 affects the proliferation of the U251 cell line.
[0050] See also Figure 8 In WT and BRCA1 KO LN229 cell lines treated with or without LPS, the homologous recombination (HR) level of the BRCA1 KO group was lower than that of the WT group, indicating that the HRR ability of BRCA1 KO LN229 was significantly reduced, suggesting that BRCA1 affects the HRR of U251 cells.
[0051] See also Fig. 9 The homologous recombination (HR) level of BRCA1 KO with or without LPS treatment was lower than that of WT, indicating that the HRR capacity of BRCA1 KO U251 was significantly reduced, indicating that BRCA1 affects the HRR of U251 cells.
[0052] LPS promoted DNA damage in the WT group, but not in the BRCA1 KO group. These results suggest that NF-κB promotes HRR in GBM through BRCA1.
[0053] The experimental methods and steps involved in this embodiment can be completed by those skilled in the art according to the following methods and steps:
[0054] 1. Immunofluorescence
[0055] 1) Cell plating: When the cell density reaches the level suitable for subculturing, discard the culture medium, wash once with high-temperature sterilized PBS, aspirate the PBS, add an appropriate amount of 0.25% trypsin, and place in a cell culture incubator for digestion. When the cells become round or nearly round, take them out, add an appropriate amount of complete culture medium to neutralize them, count the cells, and take 5×10 4 The cells were plated into a pre-prepared well plate with a cell slide and placed in an incubator for culture.
[0056] 2) Cell fixation: Take the cells out of the cell culture incubator, discard the culture medium, wash twice with PBS, aspirate the residual PBS, then add 4% paraformaldehyde and let it stand at room temperature for 15 minutes. After standing, discard the paraformaldehyde and wash three times with PBS.
[0057] 3) Neutralization: Add 50 mM NH 4 Cl, stand at room temperature for 15 min, then wash three times with PBS, and discard the PBS.
[0058] 4) Permeabilization: Add an appropriate amount of 0.2% Triton-X100 to the well plate, let it stand at room temperature for 15 minutes, and then wash three times with PBS.
[0059] 5) Blocking: Add an appropriate amount of blocking solution or 5% fetal bovine albumin solution prepared in PBS to the well plate, let it stand at room temperature for 1 hour, and then wash once with PBS.
[0060] 6) Primary antibody incubation: Dilute the target primary antibody in an appropriate ratio, 30 μL per well. Take out the cell slide and drain it, then invert it on the added primary antibody and incubate it in a 4°C refrigerator overnight.
[0061] 7) Secondary antibody incubation: After the primary antibody incubation is completed, wash with PBS three times, 5 min each time, select a secondary antibody with appropriate properties corresponding to the primary antibody, dilute it in an appropriate ratio, and then invert the slide on the added secondary antibody in the same way as the primary antibody incubation. Let it stand at room temperature away from light for 1 hour. After incubation is completed, wash with PBS three times, 5 min each time (pay attention to avoid light during the whole process).
[0062] 8) Staining cell nuclei: Add an appropriate amount of Hoechst 33342, incubate the slide upside down at room temperature for 15 minutes, then wash twice with PBS and ddHO. 2 O wash twice.
[0063] 9) Sealing: Add an appropriate amount of sealing medium on the slide, then place the drained slide upside down on the sealing medium and let it stand at room temperature overnight (be sure to avoid light).
[0064] 10) Image acquisition: Use a Leica SP5 confocal microscope to acquire images of the above slides and save the images for subsequent analysis.
[0065] 2. CRISPR-Cas9 (Gene Editing)
[0066] 1) The corresponding sgRNA primers for EZH2 and p65 were designed using an online tool website (http: / / crispr-era.standford.edu / index.jsp), and sequences with higher scores were screened. The website for predicting off-targets in Zhang Feng's laboratory (https: / / cm.jefferson.edu / Off-Spotter / ) was used to predict off-targets, and sequences with fewer off-targets were selected for subsequent vector construction. The designed primers were compared using nucleotide BLAST in NCBI to ensure that the designed sgRNAs were on the same exon, and the final sgRNA sequence was determined for subsequent vector construction.
[0067] 2) Enzyme digestion vector: The vector is lentiCRISPR v2 (addgene, #52961), and the enzyme digestion system is as follows:
[0068] Buffer 3.120μL
[0069] Plasmid 5 μg
[0070] BsmBI 2.5 μL
[0071] H 2 Oto 200μL
[0072] Total volume 200 μL
[0073] The enzyme digestion conditions were 55°C water bath and the enzyme digestion time was 1 hour.
[0074] 3) Gel excision to recover the fragments after enzyme cleavage. According to the kit, the target fragments cut by the blue light gel exciter are recovered for subsequent experimental use.
[0075] 4) Preparation of sgRNA, the system is as follows:
[0076] sgRNA Forward (10nM) 1 μL
[0077] sgRNA Reverse(100nM)1 μL
[0078] H 2 O (autoclaved water) 8 μL
[0079] Total volume 10 μL
[0080] Annealing conditions: 95°C in a water bath and slowly cooled to room temperature.
[0081] 5) Connection: Connect the annealed primer to the linear vector cut by enzyme. The connection system is as follows:
[0082] 1 μL of linearized Cas9 vector
[0083] Annealed sgRNA 10 μL
[0084] T4 DNA ligase 2 μL
[0085] T4 ligase buffer 2 μL
[0086] H 2 O (autoclaved water) 5 μL
[0087] Total volume 20 uL
[0088] Connection conditions: room temperature overnight
[0089] 6) Transformation: Using Stbl3 competent medium, add all the above ligation products to an appropriate amount of Stbl3 competent medium, place on ice for 30 minutes, then heat shock in a 42°C water bath for 1 minute, then place on ice for 5 minutes, then add 1 mL of autoclaved bacterial culture medium (LB medium), place in a 37°C bacterial culture shaker, 200 rpm, and culture for 1 hour.
[0090] 7) Plate coating and bacterial picking: After the ligation products of the above transformation are taken out, they are centrifuged at 5000g for 5 minutes. Part of the LB culture medium is discarded and about 100μL is kept for plate coating. The coated bacterial plate is then placed in a 37℃ bacterial incubator for overnight culture. On the second day, when the colonies on the bacterial plate grow to an appropriate size, the bacterial plate is taken out and a certain number of monoclonal colonies are picked for colony PCR to select the correct colonies for subsequent sequencing.
[0091] The colony PCR system and conditions are as follows:
[0092] TaKaRa Ex Taq (5 U / μl) 0.25 μL
[0093] 10×Ex Taq Buffer (Mg 2+ free)5 μL
[0094] MgCl 2 (25 mM) 4 μL
[0095] dNTP Mixture (2.5 mM) 4 μL
[0096] Primer Forward (10nM) 1 μL
[0097] Primer Reverse(10nM)1 μL
[0098] Template2 μL
[0099] H2O (autoclaved water) to 50 μL
[0100] Total volume 50 μL
[0101] The reaction conditions are:
[0102] 95℃30 sec
[0103] 98℃10 sec
[0104] 55℃30 sec
[0105] 72℃1 min
[0106] 72℃2min
[0107] 12℃hold
[0108] Prepare 1% agarose gel and perform electrophoresis on the PCR products of the above colonies. If there is a correct fragment, select the corresponding colony for amplification.
[0109] 8) Extract plasmid and send for sequencing: Add the correct colony mentioned above to an appropriate amount of LB, place it in a shaker at 37°C and 200 rpm for overnight culture. When the cultured bacterial solution becomes turbid, take it out and extract the plasmid according to the requirements of the kit. Send the extracted plasmid to the company for sequencing analysis, and retain the correct plasmid for subsequent use.
[0110] Example 3
[0111] CAPE, Olaparib alone, and CAPE + Olaparib combined were used to observe cell survival rate in LN229 or U251 cell lines.
[0112] This example uses CRISPR / Cas9 to knock out BRCA1 and p65 in LN229 or U251 cell lines. This example uses DMSO (control group) or PARP inhibitors to treat WT and p65 KO LN229 cells, respectively. PARP inhibitors include Olaparib, Veliparib, Talazoparib, Niraparib and Rucaparib, and evaluates the inhibitory effects of the above five small molecule PARP inhibitors on the growth of WT and p65 KO GBM cells. The results are shown in Fig.10 Compared with WT control cells, all five small molecule PARP inhibitors specifically inhibited the proliferation of p65 KO cells, among which Olaparib had the highest selection efficiency for p65 KO cells.
[0113] This example also used increasing doses of Olaparib combined with increasing doses of CAPE to treat LN229 or U251 cell lines for 24 hours, and used CCK8 kit to detect proliferation, and Combenefit to calculate the synergistic effect score. For the results, please refer to Fig.11 , wherein the analysis found that Olaparib (PARP inhibitor) and CAPE (NF-κB inhibitor) can eliminate each other's drug resistance. In this embodiment, the synergistic effect is best when the molar ratio of CAPE to Olaparib is (35-40):1, and the more preferred molar ratio of CAPE to Olaparib is 37.5:1.
[0114] This example also observed the cell survival rate on LN229 cell line by using CAPE and Olaparib alone, and CAPE + Olaparib in combination. CAPE (concentration: 3μM), Olaparib (concentration: 80nM) alone, and CAPE (concentration: 3μM) + Olaparib (concentration: 80nM) in combination were used to observe the cell survival rate on LN229 and U251 cell lines. The results are shown in Figure 12-14The analysis found that CAPE and Olaparib had basically no effect on the LN229 cell line when used alone, but CAPE and Olaparib had a significant growth inhibitory (decreased) and survival rate reducing effect on the LN229 cell line when used in combination, and the combination of different concentrations of CAPE and Olaparib had a significant growth inhibitory (decreased) and survival rate reducing effect.
[0115] in:
[0116] See also Fig.12 Compared with the treatment of LN299 and U251 cells with CAPE or Olaparib alone, the combined treatment of LN299 and U251 cell lines with CAPE and Olaparib significantly inhibited the ability of LN299 and U251 cell lines to form clones.
[0117] See also Fig.13 Compared with the treatment of LN299 and U251 cells with CAPE or Olaparib alone, the combined treatment of LN299 and U251 cell lines with CAPE and Olaparib significantly increased the apoptosis of LN299 and U251 cell lines.
[0118] See also Fig.14 Compared with the treatment of LN299 and U251 cells with CAPE or Olaparib alone, the combined use of CAPE and Olaparib to treat LN299 and U251 cell lines can significantly increase the immunofluorescence detection levels of LN299 and U251 cell lines, indirectly reflecting that the combined use of CAPE and Olaparib to treat LN299 and U251 cell lines can significantly increase the apoptosis of LN299 and U251 cell lines.
[0119] Compared with the control group, when CAPE was used alone, the clone formation was reduced to about 35%, and apoptosis increased by about 20%; when Olaparib was used alone, the clone formation was reduced to about 50%, and apoptosis increased by about 40%; when CAPE and Olaparib were used in combination, the clone formation was reduced to 5%, and apoptosis increased to about 65%. Olaparib (PARP inhibitor) and CAPE (NF-κB inhibitor) eliminated each other's drug resistance. Figure 12-14 The results of this study showed that the combination of CAPE and Olaparib produced a synthetic lethal effect on GBM compared with CAPE or Olaparib alone.
[0120] The experimental methods and steps involved in this embodiment are:
[0121] 1. Clone formation experiment
[0122] 1) When the cell density reaches the subculture requirement, subculture and count the cells at the same time. Select 500-100 cells per well according to cell characteristics such as cell growth rate, and then evenly spread them in a 6-well plate, and then continue to culture them in the cell culture incubator.
[0123] 2) Change the cell culture medium every 3-4 days. When the culture reaches about 14 days, or when the clones in the well plate reach an appropriate size, remove the well plate from the incubator.
[0124] 3) Use a suction pump to remove the old culture medium, wash with PBS 2-3 times, and then add 500μl of 4% paraformaldehyde to fix the cells. The conditions are: let it stand at room temperature for 30 minutes, and discard the paraformaldehyde after standing.
[0125] 4) After discarding the methanol, add 0.1% crystal violet stain for staining. The conditions are: let stand at room temperature for 15 minutes, then recover the crystal violet stain, wash with double distilled water, and dry the well plate after washing.
[0126] 5) Take a photo of the dried well plate and save the image for subsequent analysis.
[0127] 2. Cell apoptosis experiment
[0128] 1) GBM cells in the logarithmic growth phase were treated with medium replacement and 10 μM etoposide was added to treat the cells for 24 hours.
[0129] 2) Select appropriate trypsin to digest the cells, then centrifuge at 300g for 5 minutes, discard the supernatant, wash the cells once with PBS, then resuspend the cells and count the cells.
[0130] 3) Take 5×10 5 The resuspended cells were centrifuged at 500 g for 5 minutes, the supernatant was discarded, and the cells were washed once with PBS, and then 500 μL of diluted 1x Annexin V Binding Buffer was added to resuspend the cells.
[0131] 4) Add 5 μL AV staining solution and 5 μL PI staining solution.
[0132] 5) Vortex gently to mix, and incubate at room temperature in the dark for 30 minutes.
[0133] 6) After the above reaction is completed, immediately use the flow analyzer to detect it. Note that it should be filtered with a 300-mesh filter membrane before the machine detection.
[0134] 3. Cell cycle experiment
[0135] 1) Use appropriate methods to establish a detection model, set up a negative control group, and collect cells; calculate the required volume of staining working solution based on the number of samples, and incubate each sample with 500 μL of working solution; before use, prepare the RNase A:PI working solution at a volume ratio of 1:9 to prepare the staining working solution.
[0136] 2) After washing the cells with PBS, 1x106 cells were fixed with 1 mL of 70% ice-cold ethanol at 4°C overnight.
[0137] 3) 1500 rpm, 5 min, discard the supernatant (ethanol), resuspend in 1 mL PBS into a 1.5 mL tube (prepare working solution and labeled tubes during this period).
[0138] 4) Centrifuge at 1500 rpm for 3 min, centrifuge for 30 s, and then at 1500 rpm for 3 min. When all the precipitates are stably attached to the bottom of the tube, discard the supernatant (PBS).
[0139] 5) Add 500 μL of the PI / RNase A staining solution prepared in advance and incubate at room temperature away from light for 30 minutes (go downstairs and turn on the flow cytometry machine at this time).
[0140] 6) Test on the computer and record the red fluorescence at the excitation wavelength of 488nm.
[0141] The above-mentioned embodiments only express several implementation methods of the present invention, and the description is relatively specific and detailed, but it cannot be understood as limiting the scope of the invention patent. It should be pointed out that for ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, and the present invention is also intended to include these modifications and modifications.
Claims
1. A pharmaceutical composition, characterized in that: It comprises a PARP inhibitor and a NF-κB inhibitor, wherein the molar ratio of the NF-κB inhibitor to the PARP inhibitor is (35-40):1; the PARP inhibitor is Olaparib, and the NF-κB inhibitor is CAPE.
2. The pharmaceutical composition according to claim 1, characterized in that: The molar ratio of the NF-κB inhibitor to the PARP inhibitor is 37.5:
1.
3. A method for preparing the pharmaceutical composition according to any one of claims 1 to 2, characterized in that: The method is obtained by mixing the PARP inhibitor and the NF-κB inhibitor in a molar ratio.
4. Use of the pharmaceutical composition according to any one of claims 1 to 2 in the preparation of a drug for treating glioblastoma.
5. Use of the pharmaceutical composition according to claim 4 in the preparation of a drug for treating glioblastoma, characterized in that: The glioblastoma cells include LN229 and / or U251.
6. Use of the pharmaceutical composition according to claim 4 in the preparation of a drug for treating glioblastoma, characterized in that: The PARP inhibitor and the NF-κB inhibitor in the pharmaceutical composition induce glioblastoma lethality by jointly inhibiting NF-κB and PARP.
7. Use of the pharmaceutical composition according to claim 6 in the preparation of a drug for treating glioblastoma, characterized in that: The PARP inhibitor and the NF-κB inhibitor in the pharmaceutical composition induce glioblastoma lethality by jointly inhibiting the co-expression of p65 and BRCA1.
